AMD

Exploring sustained drug delivery options in ophthalmology

Current options, challenges in developing novel therapies.

Genentech's Susvimo, formerly PDS with ranibizumab, receives US FDA approval

Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

PDS with ranibizumab in nAMD offers similar results to ranibizumab monthly injections

Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.

Brolucizumab injection improves vision in eyes with neovascular AMD

September 11, 2021

In a presentation at the EURETINA 2021 Virtual Congress, Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.

Optimizing Care For Patients With Retinal Disorders

August 25, 2021

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.